drugset / Trial / NCT06128460
Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer.
NaSingle-groupOpen-labelTreatment
Summary
Locally advanced cervical cancer (stage IB3, IIA2) patients with postoperative risk factors need better treatment. We initiated a clinical study to explore the effectiveness of adjuvant chemoradiotherapy followed by Zimberelimab for these patients.
Timeline
- Start
- 2023-12-01
- Primary completion
- 2025-12-01
- Completion
- 2029-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zimberelimab | Monoclonal antibody | 240 mg | Intravenous |
| Background | Cisplatin | Other / unclassified | 40 mg/m2 | — |